Association of serum homocysteine with major depressive disorder: results from a large population-based study. by Nabi, H. et al.
   
 
 
 
 
Serveur Acade´mique Lausannois SERVAL serval.unil.ch
Author Manuscript
Faculty of Biology and Medicine Publication
This paper has been peer-reviewed but does not include the final publisher
proof-corrections or journal pagination.
Published in final edited form as:
Title: Association of serum homocysteine with major depressive disorder:
results from a large population-based study.
Authors: Nabi H, Bochud M, Glaus J, Lasserre AM, Waeber G,
Vollenweider P, Preisig M
Journal: Psychoneuroendocrinology
Year: 2013 Oct
Issue: 38
Volume: 10
Pages: 2309-18
DOI: 10.1016/j.psyneuen.2013.04.018
In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains
an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article.
 1
Association of serum homocysteine with major depressive disorder: Results from a 
large population-based study 
 
 
 
Running title: homocysteine and depression 
 
 
Hermann Nabi1,2* , Murielle Bochud3 , Jennifer Glaus4, Aurélie M. Lasserre4, Gérard Waeber5, 
Peter Vollenweider5**, Martin Preisig4** 
 
                                                                          
1. INSERM, U1018, Centre for Research in Epidemiology and Population Health, Epidemiology of 
occupational and social determinants of health, F-94807, Villejuif, France 
2. Université de Versailles St Quentin, UMRS 1018, F-94807, Villejuif, France 
3. Institute of Social and Preventive Medicine (IUMSP), Lausanne University Hospital and 
University of Lausanne, Lausanne, Switzerland, 
4. Department of Psychiatry, Lausanne University Hospital, Lausanne, Switzerland 
5. Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, 
1011, Lausanne, Switzerland 
 
 
 
 
 
 
 
Word count:  
Abstract: 175 
Manuscript: 5167 
 
 
 
 
 
*Corresponding author & address 
INSERM, U1018 
Hôpital Paul Brousse/Bâtiment 15/16 avenue Paul Vaillant Couturier 
94807 VILLEJUIF CEDEX, FRANCE 
Tel: + 33 (0)1 77 74 74 21 
Fax: + 33 (0)1 77 74 74 03 
Email: Hermann.Nabi@sinserm.fr 
 
** Joint last authors 
 2
ABSTRACT 
Background: Studies on the association between homocysteine levels and depression have shown 
conflicting results. To examine the association between serum total homocysteine (tHcy) levels and 
major depressive disorder (MDD) in a large community sample with an extended age range.  
 
Methods: A total of 3,392 men and women aged 35 to 66 years participating in the CoLaus study 
and its psychiatric arm (PsyCoLaus) were included in the analyses. High tHcy measured from fasting 
blood samples was defined as a concentration ≥ 15 μmol/L. MDD was assessed using the semi-
structured Diagnostic Interview for Genetics Studies.  
 
Results: In multivariate analyses, elevated tHcy levels were associated with greater odds of meeting 
the diagnostic criteria for lifetime MDD among men (OR=1.71; 95% CI, 1.18-2.50). This was 
particularly the case for remitted MDD. Among women, there was no significant association 
between tHcy levels and MDD and the association tended to be in the opposite direction (OR= 0.61; 
95% CI, 0.34-1.08). 
 
Conclusions: In this large population-based study, elevated tHcy concentrations are associated with 
lifetime MDD and particularly with remitted MDD among men.  
 
Keywords: Homocysteine, major depressive disorder, population-based study 
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INTRODUCTION 
           Elevated levels of blood total homocysteine (tHcy), a sulphur-based amino acid, have been 
shown to be associated with an increased risk for cardiovascular disease (CVD) (Welch and 
Loscalzo, 1998). A meta-analysis of prospective studies found that increments in tHcy 
concentrations result in a significant  increased risk of CVD, coronary heart disease (CHD), and 
stroke, independently of conventional risk factors (Bautista et al., 2002; Holmes et al., 2011). Adding 
tHcy to the Framingham risk score strongly improved the prediction of CVD in the Multi-Ethnic 
Study of Atherosclerosis (MESA) and National Health and Nutrition Examination Survey (NHANES-
III) cohorts (Veeranna et al., 2011). However, no major randomized trial has shown homocysteine-
lowering therapies to have a major impact on cardiovascular events (Bonaa et al., 2006; Lee et al., 
2010), rendering the causality of the tHcy-CVD link uncertain. 
In addition to being independent risk factor for CVD, several studies suggested a connection 
between elevated tHcy levels and psychiatric disorders, particularly depression (Forti et al., 2010; 
Muntjewerff et al., 2006; Refsum et al., 2006) . Accordingly, tHcy has been proposed as a candidate 
in the pathophysiological mechanism through which depression may influence CVD outcomes 
(Chellappa and Ramaraj, 2009). 
However, the case-control and population-based studies that have examined the association 
between tHcy levels and depression have produced inconsistent findings. Indeed, some of them 
have documented an association between tHcy levels and depression (Almeida et al., 2004; Bjelland 
et al., 2003; Dimopoulos et al., 2007; Forti et al., 2010; Kim et al., 2008; Sachdev et al., 2005; 
Tolmunen et al., 2004) , whereas others did not replicate these findings (Kamphuis et al., 2007; 
Penninx et al., 2000; Ramos et al., 2004; Tiemeier et al., 2002). Furthermore, these studies had 
several limitations.  
First, the majority of them were conducted in older adults (Almeida et al., 2008; Byers et al.; 
Morris et al., 2003b; Refsum et al., 2006). Accordingly, it remains unclear whether the association 
between tHcy and depression also exists in younger samples. Second, almost all the studies with 
positive findings (Almeida et al., 2004; Almeida et al., 2008; Bjelland et al., 2003; Dimopoulos et al., 
2007; Forti et al., 2010; Kim et al., 2008; Sachdev et al., 2005; Tolmunen et al., 2004) have applied 
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depression rating scales, rather than structured diagnostic interviews that yield standardized 
criteria for mental disorders at the diagnostic level. Besides the moderate risk of misclassification of 
current depressive symptoms (Eaton et al., 2000; Myers and Weissman, 1980) studies that solely 
employ rating scales can hardly take into account past psychopathology, given that such scales 
generally only cover recent symptoms. However, the inclusion of lifetime rather than current 
psychopathology is a critical issue for episodic disorders, such as depression given that the influence 
of depressive symptoms over time is likely to be more relevant than the temporary presence of 
symptoms at a given point of time.  . Another critical shortcoming of previous studies is the 
incomplete consideration of potential confounding factors, such as vascular risk factors that are 
known to be associated with both tHcy levels and depression(Katon et al., 2004; Refsum et al., 2006; 
Rubin et al., 2010). None of the previous studies adjusted for all the main vascular risk factors.  For 
example, Tolmunen et al (Am J Clin Nutr, 2004) adjusted for smoking and alcohol intake, but not for 
body mass index,  diabetes, hypertention, cholesterol, etc.  In sum, the relationship between tHcy 
with depression is still only partically understood and requires further study.  
The objectives of the present study were 1) to explore the association between serum tHcy 
levels and major depressive disorder in a large population-based sample of men and women with an 
extended age range; and 2) to examine whether the association between tHcy levels and major 
depression is independent of behavioural and vascular risk factors after controlling for 
sociodemographic characteristics.  
 
MATERIAL & METHODS 
Study sample 
Data are drawn from the CoLaus (Firmann et al., 2008) and PsyCoLaus (Preisig et al., 2009) 
studies. Briefly, the CoLaus study based on a sample of 6,733 individuals (3,544 women and 3,189 
men) randomly selected from the residents of the city of Lausanne (Switzerland) took place from 
2003-2006. Its major aims are to determine the prevalence of CVD risk factors and assess potential 
genetic determinants. The inclusion criteria were: a) written informed consent and b) age between 
35–75 years and c) Caucasian origin. The Caucasian origin was adopted given the strong genetic 
 5
orientation if the study. PsyCoLaus is the psychiatric arm of the CoLaus study. All participants of the 
CoLaus study aged 35 to 66 years (n = 5535) were systematically invited to also participate in the 
psychiatric evaluation. A total of 3717 (67%) individuals underwent the psychiatric assessment 
between 2004 and 2008. After excluding participants with missing data (n=325), the analytic 
sample of the present study included 3,392 participants. The Institutional Ethics Committee of the 
Faculty of Medicine of the University of Lausanne approved the CoLaus and the PsyCoLaus studies. 
All participants signed a written informed consent after having received a detailed description of 
study objectives. 
Measures 
Serum total homocysteine (tHcy): Participants were invited to attend the outpatient clinic at 
the Centre Hospitalier Universitaire Vaudois (CHUV) in the morning after an overnight fast for 
clinical examination. Venous blood samples (50 ml) were drawn for each participant and most 
clinical chemistry assays were performed by the CHUV Clinical Laboratory on fresh blood samples. 
Serum tHcy level was determined with high-performance liquid chromatography (Firmann et al., 
2008). Maximum inter- and intra-batch CVs were 3.1% and 2.9%, respectively. Elevated serum tHcy 
was defined as a concentration ≥ 15 μmol/L based on the prevailing agreement in the literature 
(Malinow et al., 1999; Nygard et al., 1997; Ueland et al., 1993). 
Major depressive disorder (MDD): MDD was assessed using validated French version of the 
semi-structured Diagnostic Interview for Genetics Studies (DIGS) (Nurnberger et al., 1994). The 
DIGS was developed by the National Institute of Mental Health (NIMH) Molecular Genetics Initiative 
in order to obtain a more precise assessment of phenotypes through a wide spectrum of the 
Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) Axis I criteria. The 
applied semi-structured interview allows for the assessment of current and past episodes of MDD. 
The French translation of the DIGS ( LEBOYER M, BARBE B, GORWOOD P et al. Interview 
Diagnostique pour les Etudes Génétiques, Paris, INSERM, 1995.) was extensively tested and 
revealed excellent inter-rater reliability (kappa=093) and a slightly lower 6-week test-
retest reliability (kappa=0.62) for MDD (PREISIG M, FENTON BT, MATTHEY ML, BERNEY A, 
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FERRERO F. Diagnostic interview for genetic studies (DIGS): inter-rater and test-retest reliability 
of the French version. European Archives of Psychiatry & Clinical Neuroscience 1999;249:174-
179). In order to also assess algorithmically defined depressive syndromes below the DSM-
IV threshold (brief and recurrent brief depression, minor depression), the one-week 
duration specification of the original DIGS in the depression screen was removed for the 
PsyCoLaus study. Interviewers were psychologists or psychiatrists trained over a two-month 
period. 
Covariates: Sociodemographic measures included age, sex, marital status and educational 
level. Behavioural CVD risk factors were assessed using responses to a standardized questionnaire 
and categorised as follows: smoking status (never, former and current), alcohol consumption [none, 
low (1-6 drinks/week), moderate (7-13/week) and high (14+/week)]. Physical activity (none, once 
a week, and twice a week) was assessed by asking participants “how many times a week do you 
engage in 20 minutes of physical activity.”  The following biological CVD risk factors were 
standardly measured at clinical examination after an overnight fast  and included in the analyses as 
categorical variables: overweight/obesity (BMI ≥ 25 kg/m2 or ≥30 kg/m2),  high total cholesterol 
(≥6.2mmol/L), high triglycerides (≥2.2mmol/L ), hypertension (systolic and diastolic blood 
pressures ≥140/90 mm Hg or presence of antihypertensive medication), diabetes (fasting plasma 
glucose ≥ 7.0 mmol/L or presence of oral hypoglycaemic or insulin treatment), albuminuria 
(Albumin/creatinine ratio (ACR)> 30 mg/g)(Marti et al., 2011) and self-reported doctor diagnosis of  
CVD event (yes/no). We also included additional covariates such as current diuretic, and 
antidepressant use assessed by recording all the prescribed drugs taken by each participant. Finally, 
participants were asked whether they were taking vitamin supplements (yes/no) on a regular basis. 
No specific information allowing differentiating intakes of vitamin B6, B11 and B12 was collected. 
Statistical analyses 
For comparisons of data on tHcy levels and MDD as a function of sample characteristics, chi-
square tests were used. The association between tHcy levels and MDD has been examined using five 
serially adjusted logistic regression models. The interaction of sex with tHcy in relation to MDD was 
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borderline significant (p=0.06). We consider this interaction to be sufficiently significant to warrant 
separate analyses by sex, considering the gender differences in depression and tHcy concentrations 
reported previously(Jacques et al., 1999; Piccinelli and Wilkinson, 2000).  In model 1, the sex-
specific odds ratios (OR) were adjusted for sociodemographic characteristics. In models 2 to 4, OR 
were additionally adjusted for health-related behaviours, biological risk factors and 
medication/vitamins use, respectively. We adjusted model 5 for all of the covariates outlined above. 
In order to test the robustness of our findings, we undertook several post-hoc analyses. First, we 
conducted a multinomial logistic regression to examine the association of tHcy levels with remitted 
and current MDD. Second, we divided tHcy levels into 4 categories (<9 µmol/L, 9 -11.9 µmol/L, 12- 
14.9µmol/L, and ≥ 15 µmol/L) in order to check for a dose-response relation with MDD as done 
previously (Bjelland et al., 2003). Third, we stratified the analyses by age groups (<43 y, 43-49 y, 50-
57 y, ≥58 y) to test for a possible effect modification by age. We considered a result to be statistically 
significant at p <0.05. Analyses were performed using Stata 12 (StataCorp. College Station, TX, USA)” 
 
 
RESULTS 
The prevalence of elevated serum tHcy (≥15µmol/L) was 9.6% in men and 3.2% in women. 
For MDD, the lifetime prevalence was 31.5% in men and 53.9% in women.  Specifically, the 
prevalence of remitted and current MDD was 25.9% and 5.6%, respectively, in men. The 
corresponding figures in women were 44.3% and 9.6%. The characteristics of the men and women 
according to tHcy levels are presented in table 1. In men, higher tHcy concentrations were 
associated with older age, current smoking, physical inactivity, overweight/obesity, high total 
cholesterol and triglycerides, hypertension, diabetes, history of CVD, albuminuria, diuretics and 
vitamins use (all p ≤0.03). In women, higher tHcy concentrations were associated with older age, 
lower educational level, not being married, hypertension, diabetes and diuretics use (all p ≤0.007).  
The characteristics of the men and women with and without MDD are summarized in table 2. 
Compared to their non-depressed counterparts, depressed men were more likely to be younger, 
with higher educational level, not married, current smokers, overweight or obese, and 
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antidepressants and vitamins users (all p ≤0.03). Depressed women were more likely to be younger, 
not married, current smokers, physically inactive, and antidepressants users (all p ≤0.04). 
Table 3 shows the OR estimating the association between tHcy levels and MDD in men and 
women. In model 1, when adjustments were made for sociodemographic characteristics, men with 
elevated tHcy levels had a significantly higher odds of meeting the diagnostic criteria for lifetime 
MDD (OR= 1.52; 95% CI, 1.52-2.16) compared to those with low tHcy level. After additional serial 
adjustments for health-related behaviours (model 2), biological risk factors (model 3), diuretics, 
antidepressants and vitamins use (model 4), and for all aforementioned variables (model 5), the 
magnitude of this association was increased by 37% and remained statistically significant (fully 
adjusted OR= 1.71; 95% CI, 1.18-2.50). Among women, there was no significant association between 
tHcy levels and MDD neither in model 1 (OR=0.71; 95% CI, 0.41-1.22) nor in subsequent models and 
the association tended to be in the opposite direction (fully adjusted OR= 0.61; 95% CI, 0.34-1.08). 
Post-hoc analyses 
First, the semi-structured diagnostic interview used in the present study allowed for the 
assessment of current and past (remitted) episodes of MDD. As shown in figure 1, after adjustment 
for all potential confounders as in the previous model 5, men with both remitted and current MDD 
were more likely to have an elevated tHcy level (serum concentration ≥ 15 μmol/L) than those who 
had never experienced depression, although this association only reached the level of statistical 
significance for remitted MDD. Among women, we did not observe significant associations between 
depression status and tHcy levels. The OR for both remitted and current MDD were even smaller 
than 1 (results not shown). 
Second, results of analyses having divided tHCy levels into four categories are illustrated in 
figure 2. Among men, the fully adjusted OR for MDD tended to increase with tHcy levels but was 
statistically significant only at high tHcy level (≥ 15 µmol/L). In contrast, among women they tended 
to decrease with a borderline significant reduced OR at high tHcy level (figure 2),  
Third, in the various age strata, as shown in figure 3, all fully-adjusted OR estimating the 
associations between high tHcy and MDD were largely above 1 among men. The association 
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between tHcy and MDD, however, was stronger and statistically significant only among older men 
(aged ≥58 y). 
 
DISCUSSION 
The main finding of this population-based study is that elevated serum tHcy concentrations 
were associated with greater odds of meeting the diagnostic criteria for lifetime MDD among men, 
independently of sociodemographic characteristics, health-related behaviours, biological risk 
factors and medication/vitamins use. This was the case for both remitted and current MDD, even 
though the association was more evident for remitted MDD.  For this association, we observed a 
threshold effect at levels ≥ 15 µmol/L, in line with what has been previously reported  for the 
associations between tHcy concentrations and depressive symptoms (Bjelland et al., 2003), as well 
as cardiovascular and non-cardiovascular mortality (Vollset et al., 2001). Among women, there was 
no significant association between tHcy levels and MDD and the association even tended to be in the 
opposite direction. 
Findings in the context of previous studies 
To the best of our knowledge, this is the largest population-based study examining the 
association of tHcy levels with MDD according to DSM-IV. In contrast to previous studies that used 
depressive symptoms rather than the algorithmically defined diagnosis of depression as the 
variable of interest (Almeida et al., 2004; Bjelland et al., 2003; Dimopoulos et al., 2007; Forti et al.; 
Kim et al., 2008; Loprinzi and Cardinal, 2012; Sachdev et al., 2005; Tolmunen et al., 2004), 
misclassification of MDD cases was minimized in our study. The high prevalence of MDD was most 
likely attributable to the low threshold to enter the depression section in our DIGS version. As we 
intended to also assess algorithmically defined depressive syndromes below the DSM-IV threshold, 
the one-week duration specification of the original DIGS in the screening questions for depression 
was removed. Accordingly, the large majority of the participants entered the section. We are aware 
of only four previous studies that have examined the association of tHcy with MDD according to 
DSM- III or IV (Bottiglieri et al., 2000; Morris et al., 2003a; Pascoe et al., 2012; Tiemeier et al., 2002). 
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Our study has several strengths that helped overcome the limitations of the four previous 
studies (Bottiglieri et al., 2000; Morris et al., 2003a; Pascoe et al., 2012; Tiemeier et al., 2002) that 
assessed depressive disorders as well as those that only evaluated depressive symptoms using 
depression scales (Almeida et al., 2004; Bjelland et al., 2003; Dimopoulos et al., 2007; Forti et al.; 
Kim et al., 2008; Sachdev et al., 2005; Tolmunen et al., 2004). In our study, we were able to control 
for a wide range of potentially confounding and/or mediating variables and to conduct several 
additional analyses. Moreover, our sample was recruited from the general population and was not 
restricted to older or younger age ranges.  
Although, we did not find a statistically significant interaction between tHcy and sex in 
relation to MDD, our results suggest that the association of tHcy with depression differs by sex with 
a significant positive association in men and no association, or even a tendency towards a negative 
association, in women. One reason could be that the distribution of tHcy strongly differed by sex. 
Indeed, tHcy concentrations ranged from 3.2 to 39.7 µmol/L in women, whereas these 
concentrations ranged from 4.5 to 67.1 µmol/L in men. As a consequence the prevalence of elevated 
tHcy among women (concentration of 15 µmol/L or more) was estimated at 3.2%, which was 3 
times lower than that of men. Furthermore, there was less variability in the distribution of tHcy 
levels among women as indicated by smaller variance (8.11 vs. 18.9 for men) and SD (2.8 vs. 4.4 for 
men) values. Another reason of the observed effect modification of sex on the association of tHcy 
with MDD could be due, at least in part, to the effect of sex hormones. In women, tHcy levels are 
lower before than after menopause (Hak et al., 2000; Wouters et al., 1995). Furthermore, hormone-
replacement therapy (HRT) used in post-menopausal women was found to substantially reduce 
tHcy levels (Gol et al., 2006; Walsh et al., 2000). Although data on current HRT use were not 
available, the results of our sensitivity analyses as illustrated in figure 3 did not support this latter 
possibility. Therefore, further studies have to address the issue of differential associations between 
tHcy levels and MDD by sex.  
Results from post-hoc analyses also showed that men with elevated tHcy levels had higher 
odds of meeting the diagnostic criteria for both remitted and current MDD, even if it was to a lesser 
extent for current MDD. Only 17.8% (n=90) of the 505 men with a lifetime MDD were depressed 
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(current MDD) at the psychiatric evaluation. The lack of statistical significance might have been due 
to the lower statistical power; an indication of this possibility being a wider confidence interval 
observed for the association between tHcy and current MDD in figure 1. Nonetheless, this finding is 
consistent with prior data from the Health in Men Study conducted among a community sample of 
3752 men aged 70 or older (Almeida et al., 2008). The results of this study showed that tHcy is 
associated with both current depression and a history of depression assessed based on the Geriatric 
Depression Scale and self-reported past or current treatment for depression.   
The nature of the relationship between tHcy and depression is still unclear. The fact that tHcy 
remained significantly elevated in men with past MDD episode represents an important finding that 
may help reconcile inconsistent findings and advance our understanding of the tHcy-depression 
relationship. This would mean that the raised tHcy could be a consequence of depression, even if we  
cannot rule out that the possibility that elevated tHcy causes depression. The relationship between 
tHcy and depression could be bidirectional or attributable to shared pathogenic factors such as 
genes or lifestyle that could favour both elevated tHcy levels and depression. However, lifestyle 
could also be an intermediate factor within the potentially bidirectional relationship between tHcy 
and depression. Indeed, there is some evidence from previous research showing that people with a 
history of depressive symptoms or diagnosed depression are likely to exhibit poor health 
behaviours (Breslau et al., 1993; Whooley et al., 2008), which entail an increased risk factors for 
elevated tHcy levels (Refsum et al., 2006). However, although elevated tHcy levels and MDD were 
found to be associated with physical inactivity and/or smoking in our study, the association 
between tHcy and MDD remained significant after adjustment for these variables. It should be noted 
that we were not able to take into account the trajectories of health-related behaviours over time, 
which can be influenced by the course of depression. In addition, we only took into account physical 
inactivity at the time of the interview and did not assess other relevant behaviours such as diet. For 
this reason we could not determine the potential role of nutritional deficiencies related to appetite 
loss in depression, which have been found to be associated with raised tHcy levels and folate 
deficiency(Tiemeier et al., 2002) (Bottiglieri, 1996) .  
 12
Conversely, elevated tHcy have been found to be associated with several chronic medical 
conditions such as CVD(Welch and Loscalzo, 1998) and diabetes (Targher et al., 2000) which in turn 
could predispose to depressive disorders or symptoms (Lichtman et al., 2008; Pan et al.). However, 
this explanation was not supported by our data. Indeed although medical conditions including CVD, 
diabetes, hypertension, albuminuria were associated with elevated tHcy levels, but they were not 
associated with MDD. 
Limitations 
The present findings should be interpreted in the light of several limitations. First, in spite of 
its size, this urban population-based sample is probably much healthier than the sample of previous 
studies composed of elderly people. As a consequence, the prevalence of elevated tHcy level was 
low, particularly among women, which decreased the statistical power to detect associations with 
tHcy. Secondly, the cross-sectional design of our study limits our ability to investigate the nature 
(direction of causality) of the association between tHcy and depression. Thirdly, although we have 
adjusted for a wide range of covariates, there could be residual confounding or unconsidered risk 
factors such as dietary patterns, specific vitamin status and genetics factors (Bjelland et al., 2003; 
Refsum et al., 2006) that may contribute to the relation between tHcy and depression. Finally, our 
study was conducted among men and women with Caucasian origin, which limits the generalization 
of our findings 
Conclusions 
In conclusion, the results of this large population-based study suggest that elevated serum 
tHcy concentrations were associated with increased odds of meeting criteria for a diagnosis of 
lifetime MDD and remitted MDD in men, but not in women. The fact that tHcy concentrations were 
elevated in men who met the criteria for a remitted MDD lends support to the hypothesis that 
depressive episodes lead to durably increased tHcy levels which could explain, at least partially, the 
observed links between depression, fatal and non-fatal CVD events. Further studies are needed to 
test these mechanisms and to explore whether lowering serum homocysteine levels in depressed 
patients reduces adverse CVD outcomes. 
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Table 1. Baseline characteristics of participants as a function of total homocysteine (tHcy) levels 
by sex 
 
 
  
 Men  Women 
 Serum total homocysteine (μmol/L)  Serum total homocysteine (μmol/L) 
 Mean (SD) < 15 ≥ 15 p value  Mean (SD) < 15  ≥ 15 p value 
 Number (%) 
 
 1449 (90.4) 154 (9.6)    1731 (96.8) 58 (3.2)  
Sociodemographics          
Age (years)    <0.001     0.004 
    35-42 10.3 (4.4) 510 (35.2) 34 (22.1)   8.2 (2.4) 514 (29.7) 10 (17.2)  
    43-49 10.7 (4.1) 458 (31.6) 42 (27.3)   8.9 (2.7) 521 (30.1) 19 (32.8)  
    50-57 11.5 (4.2) 342 (23.6) 48 (31.2)   9.5 (2.6) 502 (29.0) 13 (22.4)  
    ≥58  12.4 (4.2) 139 (9.6) 30 (19.4)   10.5 (3.8) 194 (11.2) 16 (27.6)  
Educational level    0.29     <0.001 
    Basic 10.3 (3.5) 202 (13.9) 58 (13.6)   9.2 (3.3) 309 (17.9) 17 (29.3)  
    Apprenticeship 11.3 (5.4) 510 (35.2) 64 (41.6)   9.5 (3.1) 609 (35.2) 31 (53.4)  
    High school/college 11.0 (4.1) 368 (25.4) 35 (22.7)   8.8 (2.5) 490 (28.3) 8 (13.8)  
    University 10.8 (3.1) 369 (25.5) 34 (22.1)   8.3 (2.1) 323 (18.7) 2 (3.4)  
Marital status    0.28     <0.001 
    Married 10.9 (4.4) 951 (65.6) 97 (63.0)   8.7 (2.7) 882 (51.0) 14 (24.1)  
    Others 11.2 (4.2) 498 (34.4) 57 (37.0)   9.4 (3.0) 849 (49.0) 44 (75.9)  
 
Health-related behaviours 
         
Smoking status    <0.001     0.06 
   Never 10.9 (3.7) 499 (34.4) 43 (27.9)   8.9 (3.1) 504 (29.1) 15 (25.9)  
   Former 10.7 (3.8) 538 (37.1) 45 (29.2)   9.0 (2.6) 752 (43.4) 18 (31.0)  
   Current 11.4 (5.5) 412 (28.5) 66 (42.9)   9.3 (3.0) 475 (27.5) 25 (43.1)  
Alcohol consumption    0.17     0.85 
    None 10.5 (6.1) 70 (4.8) 4 (2.6)   9.3 (3.1) 135 (7.8) 2 (3.4)  
    Low 10.5 (3.6) 600 (41.4) 50 (32.5)   9.0 (2.9) 805 (46.5) 27 (46.6)  
    Moderate 11.0 (3.4) 343 (23.7) 33 (21.4)   9.0 (2.5) 240 (13.9) 8 (13.8)  
    High 11.8 (5.9) 279 (19.3) 50 (32.5)   9.5 (3.1) 101 (5.8) 8 (13.8)  
    Missing 11.2 (4.3) 157 (10.8) 17 (11.0)   9.0 (2.8) 450 (26.0) 13 (22.4)  
Physical activity    0.01     0.36 
   None 11.1 (4.4) 451 (31.4) 63 (41.7)   9.2 (3.0) 526 (30.9) 23 (39.7)  
   Once a week 10.9 (4.7) 191 (13.2) 17 (11.3)   8.6 (2.3) 140 (8.2) 1 (1.7)  
   Twice a week 10.9 (4.2) 796 (55.4) 71 (47.0)   9.0 (2.8) 1039 (60.9) 34 (58.6)  
 
Biological  risk factors 
         
Overweight/obese 11.1 (4.4) 842 (58.1) 104 (67.5) 0.02  9.3(3.1) 657 (38.0) 27 (47.4) 0.15 
Total cholesterol ≥6.2mmol/l 11.4 (4.3) 313 (22.4) 48 (31.8) 0.009  9.7 (2.7) 379 (22.5) 13 (22.4) 0.99 
Triglycerides ≥2.2mmol/l  249 (17.2) 41 (26.6) 0.004   98 (5.7) 1 (1.7) 0.20 
Hypertension 11.8 (4.5) 460 (31.7) 82 (53.2) 0.001  9.9 (3.4) 387 (22.4) 24 (41.4) <0.001 
Diabetes 11.7 (5.2) 112 (7.7) 20 (13.0) 0.02  11.2 (3.8) 46 (2.7) 5 (8.6) 0.007 
History of CVD 12.8 (7.2) 47 (3.2) 10 (6.5) 0.03  10.2 (2.7) 30 (1.7) 2 (3.4) 0.33 
Albuminuria 13.2 (8.7) 62 (4.4) 22 (14.5) <0.001  9.4 (2.7) 88 (5.1) 2 (3.6) 0.60 
 
Medications/supplements use 
         
Diuretics 12.6 (6.2) 62 (4.3) 16 (10.4) <0.001  10.7 (2.8) 74 (4.3) 9 (15.5) 0.001 
Antidepressants 10.7 (3.1) 96 (6.6) 6 (3.9) 0.19  9.2 (2.7) 208 (12.0) 6 (10.3) 0.70 
Vitamins 9.8 (3.1) 132 (9.1) 6 (3.9) 0.03  8.6 (2.4) 288 (16.6) 6 (10.3) 0.20 
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Table 2. Baseline characteristics of participants as a function of lifetime major depressive disorder 
(MDD) by sex 
 Men   Women  
 MDD  MDD  
 No Yes p value  No Yes p value 
 Number (%) 
 
1098 (68.5) 505 (31.5)   825 (46.1) 964 (53.9)  
Sociodemographics        
Age (years)   0.001    0.01 
    35-42 351 (32.0) 193 (38.2)       217 (26.3) 307 (31.8)  
    43-49 348 (31.7) 152 (30.1)   241 (29.2) 299 (31.0)  
    50-57 277 (25.2) 113 (22.4)   256 (31.0) 259 (26.9)  
    ≥58  122 (11.1) 47 (9.3)   111 (11.5) 99 (10.3)  
Educational level   0.009    0.23 
    Basic 160 (14.5) 63 (12.4)   160 (19.4) 166 (17.2)  
    Apprenticeship 404 (36.8) 170 (33.7)   295 (35.8) 345 (35.8)  
    High school/college 282 (25.7) 121 (24.0)      226 (27.4) 272 (28.2)  
    University 252 (23.0) 151 (29.9)   144 (17.5) 181 (18.8)  
Marital status   <0.001    <0.001 
    Married 758 (69.0) 290 (57.4)   476 (57.7) 420 (43.6)  
    Others 340 (31.0) 215 (42.6)   349 (42.3) 544 (56.4)  
 
Health-related behaviours 
       
Smoking status   0.03    0.02 
   Never 394 (35.9) 148 (29.3)   384 (46.5) 386 (40.0)  
   Former 404 (36.8) 179 (35.4)   243 (29.5) 276 (28.6)  
   Current 300 (27.3) 178 (35.3)   198 (24.0) 302 (31.4)  
Alcohol intake   0.20    0.81 
    No 56 (5.1) 18 (3.5)   63 (7.6) 74 (7.7)  
    Low 440 (40.1) 210 (41.6)   369 (44.8) 463 (48.0)  
    Moderate 267 (24.3) 109 (21.6)   130 (15.8) 118 (12.3)  
    High 223 (20.3) 106 (21.0)   49 (5.9) 60 (6.2)  
    Missing 112 (10.2) 62 (12.3)   214 (25.9) 249 (25.8)  
Physical activity   0.24    0.04 
   None 360 (33.1) 154 (30.8)   237 (29.1) 312 (32.9)  
   Once a week 147 (13.5) 61 (12.2)   59 (7.2) 82 (8.6)  
   Twice a week 582 (53.4) 285 (57.0)   518 (63.6) 555 (58.5)  
 
Biological  risk factors 
       
Overweight/obese 670 (61.0) 276 (54.8) 0.01  322 (39.1) 362 (37.7) 0.53 
Total cholesterol ≥6.2mmol/l 250(23.5) 111 (22.8) 0.75  184 (22.9) 208 (22.1) 0.67 
Triglycerides ≥2.2mmol/l 187 (17.0) 103 (20.4) 0.10  52 (6.3) 47 (4.9) 0.19 
Hypertension 387 (35.2) 155 (30.7) 0.07  196 (23.8) 215 (22.3) 0.47 
Diabetes 91 (8.3) 41 (8.1) 0.91  21 (2.5) 30 (3.1) 0.47 
History of CVD 36 (3.3) 21 (4.2) 0.38  14 (1.7) 18 (1.9) 0.79 
Albuminuria 56 (5.3) 28 (5.6) 0.75  39 (4.8) 51 (5.4) 0.57 
 
Medications/supplements use 
       
Diuretics 50 (4.6) 28 (5.5) 0.12  43 (5.2) 40 (4.1) 0.68 
Antidepressants 31 (2.8) 71 (14.1) <0.001  45 (5.5) 169 (17.5) <0.001 
Vitamins 81 (7.4) 57(11.3) 0.01  137 (16.6) 157 (16.3) 0.86 
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Table 3. Association between high total homocysteine (tHcy ≥ 15 μmol/L) and lifetime major 
depression disorder (MDD) in men and women 
 
 Major Depressive Disorder 
 Men  Women 
 n events/n 
total 
OR 95% CI n events/n total OR 95% CI 
Model 1   
 tHcy < 15 μmol/L 445/1449 1 936/1731 1 
 tHcy ≥ 15 μmol/L  60/154 1.52 (1.07-2.16)* 28/58 0.71 (0.41-1.22) 
       
Model 2       
tHcy < 15 μmol/L 440/1438 1 921/1705 1 
tHcy ≥ 15 μmol/L 60/151 1.56 (1.09-2.21)* 28/58 0.70 (0.41-1.21) 
       
Model 3       
tHcy < 15 μmol/L 419/1359 1 902/1668 1 
tHcy ≥ 15 μmol/L 58/149 1.47 (1.02-2.12)* 25/55 0.60 (0.34-1.05) 
       
Model 4       
tHcy < 15 μmol/L 445/1449 1 936/1731 1 
tHcy ≥ 15 μmol/L 60/154 1.67 (1.17-2.39)** 28/58 0.74 (0.42-1.28) 
       
Model 5       
tHcy < 15 μmol/L 414/1348 1 888/1644 1 
tHcy ≥ 15 μmol/L 58/146 1.71 (1.18-2.50)** 25/55 0.61 (0.34-1.08) 
* p <0.05, ** p <0.01 
Model 1: ORs adjusted for age, educational level and marital status 
Model 2: Model 1 additionally adjusted for smoking and physical activity 
Model 3: Model 1 additionally adjusted for overweight/obesity status, total cholesterol, triglycerides, history of CVD, 
hypertension, diabetes, and albuminuria 
Model 4: Model 1 additionally adjusted for antidepressants, diuretics and vitamins use 
Model 5: ORs adjusted for all aforementioned  
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Figure 1. Elevated total homocysteine (tHcy) levels (serum concentration ≥ 15 μmol/L, as the independent 
variable of interest) and risk of past (remitted) and current major depressive disorder (MDD) in men (as the 
three-category dependent variable). ORs adjusted for age, educational level, marital status, smoking, physical 
activity, overweight/obesity status, total cholesterol, triglycerides, history of CVD, hypertension, diabetes, 
albuminuria, antidepressants, diuretics and vitamins use  
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Figure 2. Total homocysteine (tHcy, as the independent variable of interest) levels and risk of lifetime major 
depressive disorder (MDD, as the dependent variable) in men and women. ORs adjusted for age, educational 
level, marital status, smoking, physical activity, overweight/obesity status, total cholesterol, triglycerides, 
history of CVD, hypertension, diabetes, albuminuria, antidepressants, diuretics and vitamins use  
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Figure 3. Elevated total homocysteine (tHcy) levels (serum concentration ≥ 15 μmol/L, as the independent 
variable of interest) and risk of lifetime major depressive disorder (MDD, as the dependent variable) in men 
and women by age groups. ORs adjusted for age, educational level, marital status, smoking, physical activity, 
overweight/obesity status, total cholesterol, triglycerides, history of CVD, hypertension, diabetes, 
albuminuria, antidepressants, diuretics and vitamins use  
 
 
 
 
